The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: essensys loss widens; Carclo demand strong

Tue, 18th Oct 2022 22:04

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

essensys PLC - London-based software and cloud services for flexible workspace industry - In year ended July 31, pretax loss widens to GBP11.1 million from GBP2.9 million a year prior. Revenue rises to GBP23.3 million from GBP22.0 million. Administrative expenses grows to GBP24.3 million from GBP16.5 million. Chief Executive Mark Furness says period was a year of "progress and resilience". "Momentum with strategic customers remains and underpins a significant pipeline of opportunities. The quality of our customer base has helped us to manage near-term headwinds such as delays to sales cycles and capital deployment, some portfolio rebalancing among our larger flexible workspace operators and the expected churn at the tail-end of our customer base," he adds.

----------

Carclo PLC - West Yorkshire-based plastic parts manufacturer - Says demand in first six months of its financial year, ending March 31 2023, has been "strong", resulting in sales marginally ahead of board expectations and ahead of the prior year. It adds: "The inflation and supply chain challenges experienced in the first half are expected to continue through the remainder of the financial year. Our initiatives to further enhance operational efficiency and to offset inflationary price increases are key focus areas for the second half. Increases in borrowing costs are expected in the second half driven by increases in both the level of debt and interest rates."

----------

Angle PLC - Surrey, England-based medical diagnostics company - Decides to close facilities in Toronto, Canada in an orderly wind down. Notes it retains its high-specification clinical laboratory facility in Plymouth Meeting, Pennsylvania, US, as its central hub for North American activities. Says decision is part of commitment to tightly control costs and focus on near-term commercialisation of Parsortix system for cancer liquid biopsy. Hopes to reduce costs by GBP2.6 million in 2023, rising to GBP4.0 million after.

----------

Aptamer Group PLC - York, England-based provider of custom services, diagnostics and therapeutics for biotechnology and pharmaceutical firms - Pretax loss in year to June narrows to GBP2.6 million versus GBP2.9 million loss in 15 months to June 30, 2021. Revenue multiplies to GBP4.0 million from GBP1.6 million. Administrative expenses rise to GBP4.4 million from GBP3.1 million. Chief Executive Arron Tolley says: "Aptamer has maintained a solid pace of progress over the past year, having seen success in both expanding current partnerships and winning new contracts. Commercial traction continues to increase in Europe, US and APAC regions." Sees strong revenue growth in current financial year.

----------

Open Orphan PLC - London-based research organisation testing infectious and respiratory disease products - Appoints Stephen Pinkerton as chief financial officer, to replace Leo Toole who will step down at end of 2022. Pinkerton is chartered accountant with over 25 years of experience in senior financial roles and has served as Commercial Financial Director of hVIVO since July 2017. Also notes Cathal Friel is reverting to Non-Executive Chair after Yamin Khan appointment of chief executive officer.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
11 Nov 2019 16:29

Open Orphan inks preferred partner deal with Ipsen Group

(Sharecast News) - Europe-focussed rare and orphan drug consulting services platform Open Orphan announced the signing of a preferred partner agreement with Ipsen Group on Monday.

Read more
11 Nov 2019 13:48

Open Orphan Inks Venn Life Preferred Partner Agreement With Ipsen

Open Orphan Inks Venn Life Preferred Partner Agreement With Ipsen

Read more
15 Oct 2019 13:11

Open Orphan Inks Health Data Platform Deal With Empiric Logic

Open Orphan Inks Health Data Platform Deal With Empiric Logic

Read more
15 Oct 2019 11:13

Open Orphan signs deal with Empiric Logic to complete Health Data platform

(Sharecast News) - Europe-focussed rare and orphan drug consulting services platform provider Open Orphan has signed a new strategic collaboration agreement with Empiric Logic, it announced on Tuesday, to build on the earlier work it had performed, and complete the build out of its 'Health Data' platform as Europe's first rare disease, advocacy-led genomic database.

Read more
25 Sep 2019 11:51

Open Orphan Loss Widens On Venn Life Sciences Combination Cost

Open Orphan Loss Widens On Venn Life Sciences Combination Cost

Read more
1 Aug 2019 17:37

Open Orphan Names Ex-Horizon Therapeutics Director As Non-Executive

(Alliance News) - Drug consulting platform Open Orphan PLC said on Thursday that it has appointed David Kelly as an independent non-executive director.Kelly, the company said, has orphan in

Read more
12 Jul 2019 11:57

Open Orphan Divests Remaining 3.1% Stake In Integumen

(Alliance News) - Open Orphan PLC has netted over GBP500,000 after selling the rest of its shares in skin-care firm Integumen PLC, Open Orphan said on Friday.The sale of the 30.1 million on

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.